Hi Daniel @RaceOncology
This may be one of the sillier questions to come across your desk but it's not going to stop me asking it.
In regards to the FTO dose escalation trial, does this need to be done on people with the relevant cancers (or a single cancer type in particular, I'm not sure how the trial would run)?
Assuming we're talking about low doses, and Bisantrene has been shown to be safe (though not without side effects) at high doses, I was wondering if such a trial could be run on a range of people similar to those trials you hear about where uni students (for example) get paid a few thousand dollars to complete a trial?
For this to work would at a minimum would require that it's ethical to do so, that there is a relatively non-invasive way of measuring baseline FTO and FTO after treatment, and that FTO inhibition in 'regular' cells would be similar to what it would be in cancer cells. Probably some or none of these things are true, but I thought it was worth asking.
Thank you in advance.
- Forums
- ASX - By Stock
- Ann: Race investor briefing & updated presentation
Hi Daniel @RaceOncologyThis may be one of the sillier questions...
-
- There are more pages in this discussion • 302 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M |
Open | High | Low | Value | Volume |
$1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9998 | $1.75 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.79 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9998 | 1.750 |
1 | 7599 | 1.730 |
1 | 581 | 1.720 |
3 | 11557 | 1.710 |
4 | 46280 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.790 | 2000 | 1 |
1.830 | 44030 | 2 |
1.840 | 10500 | 2 |
1.850 | 14500 | 3 |
1.860 | 949 | 2 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |